Top

Published in:

01-03-2009 | Preclinical Study

Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts

Authors: A. J. Batchelder, A. N. Gordon-Weeks, R. A. Walker

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

In a previous investigation reduced apoptosis was identified in normal breast tissue from cancer-containing breasts away from the cancer in comparison to age-matched normal breast from women without cancer. The hypothesis for this study was that defects in expression of apoptotic regulatory and DNA repair proteins would facilitate persistence of genetic alterations and predispose to breast cancer development. Using immunohistochemistry normal breast from 120 age-matched women (58 with breast cancer, 62 without) was analysed for proliferation, apoptosis, bcl2, BAX, caspase 3, Hsp27, Hsp70, BRCA1, ATM and BARD1. All assessments were performed without knowledge as to whether it was a cancer case or control. A significant difference was found for apoptotic index which was higher in controls (P < 0.02). There was no change in apoptotic and proliferation index with age for cancer cases unlike controls. Higher expression of bcl2 (P = 0.001) and Hsp27 (P = 0.001) was found in normal breast from cancer-containing breast in comparison to controls. There were no differences in the other proteins. Apoptosis has been found to be reduced in normal breast in a separate cohort of women with breast cancer, along with increased expression of the anti-apoptotic proteins bcl2 and Hsp27. These alterations in apoptotic regulation would enhance tumour development. Further studies are needed to examine the value of these proteins as risk markers.

Simpson PT, Reis-Filho JS, Gale T et al (2005) Molecular evolution of breast cancer. J Pathol 205:248–254PubMedCrossRef

Foote FW, Stewart FW (1945) Comparative studies of cancerous versus noncancerous breasts. Ann Surg 121:197–222PubMed

Wellings SR, Jensen HM, Marcum RG (1975) An atlas of subgross pathology of the human breast with special reference to precancerous lesions. J Natl Cancer Inst 55:231–273PubMed

Alpers CE, Wellings SR (1985) The prevalence of carcinoma in situ in normal and cancer associated breasts. Hum Pathol 16:796–807PubMedCrossRef

Page DL, Vander Zwaag R, Rogers LW et al (1978) Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst 61:1055–1063PubMed

Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative disease. New Eng J Med 312:146–151PubMedCrossRef

Page DL, Dupont WD (1990) Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66:1326–1335PubMedCrossRef

Tavassoli FA, Norris AJ (1990) A comparison of the results of long-term follow-up for atypical ductal hyperplasia and intraduct hyperplasia of the breast. Cancer 65:518–529PubMedCrossRef

McDivitt RW, Stevens JA, Lee NC et al (1992) Histologic types of benign breast disease and the risk of breast cancer. Lancet 69:1408–1414

10.

London SJ, Connolly JL, Schnitt SJ et al (1992) A prospective study of benign breast disease and the risk of breast cancer. J Am Med Assoc 267:941–944CrossRef

11.

Wang J, Constantino JP, Tan-Chin E et al (2004) Lower category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 96:616–620PubMedCrossRef

12.

Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerisation in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6:963–968PubMedCrossRef

13.

Braakhuis BJM, Tabor MP, Kummer JA et al (2003) A genetic explanation of Slaughter’s concept of field cancerisation: evidence and clinical implications. Cancer Res 63:1727–1730PubMed

14.

Deng G, Lu Y, Zlotnikov G et al (1996) Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057–2059PubMedCrossRef

15.

Larson PS, de las Morenas A, Cupples LA (1998) Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 152:1591–1598PubMed

16.

Lakhani SR, Chaggar R, Davies S et al (1999) Genetic alterations in ‘normal’ luminal and myoepithelial cells of the breast. J Pathol 189:496–503PubMedCrossRef

17.

Larson PS, de las Morenas A, Bennett SR et al (2002) Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 161:283–290PubMed

18.

Tlsty TD, Crawford YG, Holst CR et al (2004) Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 9:263–274PubMedCrossRef

19.

Ellsworth DL, Ellsworth RE, Liebman MN et al (2004) Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol 5:753–758PubMedCrossRef

20.

Larson PS, Schlecter BL, de las Morenas et al (2005) Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 23:8613–8619PubMedCrossRef

21.

Walker RA, Cowl J, Dhadly PPS et al (1992) Oestrogen receptor, epidermal growth factor receptor and oncoprotein expression in non-involved tissue of cancerous breasts. Breast 2:87–91CrossRef

22.

Jones JL, Critchley DR, Walker RA (1992) Alteration of integrin and stromal protein expression—a marker of pre-malignant change? J Pathol 167:399–406PubMedCrossRef

23.

Hassan HI, Walker RA (2001) Altered expression of epidermal growth factor receptor in non-involved tissue of cancer-containing breasts. Breast 10:318–324PubMedCrossRef

24.

Hassan HI, Walker RA (1998) Decreased apoptosis in non-involved tissue from cancer-containing breasts. J Pathology 184:258–264CrossRef

25.

Allan DJ, Howell A, Roberts SA et al (1992) Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 167:25–32PubMedCrossRef

26.

Clarke RB, Howell A, Potten CS et al (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991PubMed

27.

Shoker BS, Jarvis C, Clarke RB et al (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811–1815PubMed

28.

Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337PubMedCrossRef

29.

Schorr K, Li M, Bar-Peled U et al (1999) Gain of Bcl-2 is more potent than BAX loss in regulating mammary epithelial cell survival in vivo. Cancer Res 59:2541–2545PubMed

30.

Sabourin JC, Martin A, Baruch J et al (1994) Bcl-2 expression in normal breast during the menstrual cycle. Int J Cancer 59:1–6PubMedCrossRef

31.

Gompel A, Somai S, Chaout M et al (2000) Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65:593–598PubMedCrossRef

32.

Gee JM, Robertson JFR, Ellis IO et al (1994) Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619–628PubMedCrossRef

33.

Ciocca DR, Oesterreich S, Chamness GC et al (1993) Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 85:1558–1570PubMedCrossRef

34.

Concannon CG, Gorman AM, Samali A (2003) On the role of Hsp27 in regulating apoptosis. Apoptosis 8:61–70PubMedCrossRef

35.

Konishi H, Matsuzaki H, Tamaka M et al (1997) Activation of protein kinase B (AKT/RAC-protein kinase) by cellular stress and its association with heat shock protein HSP27. FEBS Lett 410:493–498PubMedCrossRef

36.

O’Neill PA, Shaaban AM, West CR et al (2004) Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer 90:182–188PubMedCrossRef

37.

Taylor J, Lymboura M, Pace PE et al (1998) An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79:334–342PubMedCrossRef

38.

Lambie H, Miremadi A, Pinder SE et al (2003) Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 200:207–213PubMedCrossRef

39.

Angele S, Treilleux I, Taniere P et al (2000) Abnormal expression of the ATM and P53 genes in sporadic breast carcinomas. Clin Cancer Res 6:3536–3544PubMed

40.

Angele S, Treilleux I, Bremond A et al (2003) Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 43:347–353PubMedCrossRef

41.

Angele S, Jones C, Reis Filho JS et al (2004) Expression of ATM, p53 and the MRE11-Rad50-NBSI complex in myoepithelial cells from benign and malignant proliferations of the breast. J Clin Pathol 57:1179–1184PubMedCrossRef

42.

Clarke RA, Kairouz R, Watters D et al (1998) Upregulation ATM in sclerosing adenosis of the breast. Mol Pathol 51:224–226PubMedCrossRef

43.

Yan PS, Venkataramu C, Ibrahim A et al (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626–6636PubMedCrossRef

44.

Fabian CJ, Kimler BF, Mayo MS et al (2005) Breast-tissue sampling for risk assessment and prevention. Endocr Res Cancer 12:185–213CrossRef

Title: Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts
Authors: A. J. Batchelder
A. N. Gordon-Weeks
R. A. Walker
Publication date: 01-03-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-9988-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women

The effect of thrombospondin-1 on breast cancer metastasis

Low frequency of human papillomavirus DNA in breast cancer tissue

Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy

Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors

The Women’s Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem

Keynote webinar | Spotlight on antibody–drug conjugates in cancer